Shandong Xinhua Pharmaceutical (00719) announced its annual results for the period ended December 31, 2025. The company reported revenue of 87.55 billion yuan, an increase of 3.41% year-on-year. Net profit attributable to shareholders was 2.9 billion yuan, a decrease of 38.32% compared to the previous year. Basic earnings per share stood at 0.42 yuan, and the board proposed a final dividend of 0.15 yuan per share.
Throughout the year, the company obtained 47 drug approvals, setting a new record. The pace of major innovative drug research and development accelerated. Patient enrollment for the Phase II clinical trial of OAB-14, a treatment for Alzheimer's disease, is nearly complete. Preparations for the Phase III clinical study of LXH-2301, a treatment for gout, have been initiated. LXH-1211, a drug for pulmonary arterial hypertension, received approval for Phase I clinical trials. Furthermore, the pre-IND application for LXH-2103, an innovative drug for moderate to severe pain, was completed.
The company was granted 48 patents during the year. One project received the Second Prize of the Shandong Provincial Science and Technology Progress Award, another project won the First Prize of the Shandong Science and Technology Workers Innovation Competition, one project was included in the provincial key research and development plan, and two projects were listed in the provincial major innovation task guide.
Formulation products are undergoing accelerated upgrades. In 2025, three products were selected in the 11th national centralized drug procurement round, and 31 products won bids in the follow-up volume-based procurement conducted by provincial alliances. This has led to the formation of a new generation of key formulation product groups, represented by items such as Aspirin Enteric-coated Sustained-release Tablets and Sevelamer Carbonate Tablets.
The company fully leveraged its comprehensive advantages in active pharmaceutical ingredients (APIs), maintaining stable growth in domestic sales revenue. The domestic market share of key products like Ibuprofen and Carbasalate Calcium further expanded. By capitalizing on its product and technological strengths, the company achieved significant progress in the export volume of its starch particle series, including Metamizole, Aspirin, and Ibuprofen. Exports of specialty APIs, such as Meloxicam, Glimepiride, and Sevelamer Carbonate, saw substantial year-on-year growth. The support role and development capacity of pharmaceutical intermediates were also enhanced.